Aldeyra advances RASP modulator pipeline; multiple IND submissions and trial initiations planned for 2024

Aldeyra Therapeutics, Inc.

Positive biomarker results from ADX-629 in Sjögren-Larsson Syndrome adult cohort; pediatric expansion submission expected H1 2024.
Phase 2 trial of ADX-629 in moderate alcoholic hepatitis initiated; top-line results expected H2 2024.
IND for ADX-246 submitted for phase 1 in healthy volunteers; expected to expand to atopic dermatitis patients; top-line results H2 2024.
IND for ADX-248 expected in 2024 for phase 1/2 in dry AMD with dark adaptation deficit.
De-prioritized ADX-629 in chronic cough and idiopathic nephrotic syndrome; new preclinical RASP modulator program in metabolic disease initiated.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.